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Purpose of the study
Selection of initial antiretroviral therapy (ART) may be
informed by factors such as efficacy, adverse effects, and
cost. This study assessed the lifetime cost-effectiveness
of atazanavir-ritonavir (ATV/r) versus lopinavir-ritonavir
(LPV/r) in HIV patients initiating first-line ART.
Methods
A Markov microsimulation model was developed to
project lifetime health-related outcomes, costs, quality-
adjusted life years (QALYs), and cost-effectiveness of
ATV/r versus LPV/r, both with tenofovir-emtricitabine,
as first-line ART. Virologic suppression, baseline charac-
teristics, state transition probabilities, cholesterol
changes, and adverse effects were based on 96-week
CASTLE results. HIV-related mortality, opportunistic
infection (OI) and AIDS rates, coronary heart disease
(CHD) risk, treatment adherence, costs, and utilities
were obtained from published sources. Costs were
reported in 2009 US dollars. Sensitivity analyses were
conducted to assess the robustness of study results.
Summary of results
Compared with patients initiating LPV/r, patients initiat-
ing ATV/r were estimated to have longer time in first-
line therapy, fewer cases of AIDS, OI, CHD, and diar-
rhea, more cases of hyperbilirubinemia (HB), and higher
costs. While absolute survival was similar, patients initi-
ating ATV/r were predicted to have longer quality-
adjusted survival. Overall, ATV/r added 0.26 QALYs at
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Table 1
Health-Related
Outcomes
Time on First-Line
Treatment
(months)
AIDS cases (per
1000 patient
years)
OI cases (per
1000 patient
years)
CHD cases (per
1000 patient
years)
Diarrhea cases (per
1000 patient years)
HB cases (per
1000 patient
years)
Absolute
Survival (life
years)
LPV/r 70.7 20.054 0.519 5.511 6.262 0.247 18.51
ATV/r 97.3 19.081 0.443 5.437 1.272 6.986 18.52
Cost, QALY, and
Cost-
Effectiveness
Cost Incremental Cost Quality-
Adjusted
Survival (QALY)
Incremental
QALY
Incremental Cost-
Effectiveness
LPV/r $269,160 – 10.761 ––
ATV/r $275,986 $6,826 11.020 0.258 $26,421
Broder et al. Journal of the International AIDS Society 2010, 13(Suppl 4):P234
http://www.jiasociety.org/content/13/S4/P234
© 2010 Juday et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.a cost of $6,826, producing an ICER of $26,421 per
QALY gained. Sensitivity analyses indicated that at a
willingness to pay threshold of $50,000 per QALY,
ATV/r was cost effective 94% of the time. Table 1
Conclusions
Accounting for both lifetime costs and QALYs, ATV/r
is cost effective (less than $50,000 per QALY) compared
with LPV/r in HIV patients initiating first-line ART.
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